Recently, Sydney-based biological diagnostic technology company Atomo Diagnostics had completed a round of finance, of which the total number was 3.5 million dollars. Investors include the Global Health Investment Fund supported by the well-known Gates Foundation. Atomo is mainly focused on the development of rapid detection of a variety of infectious diseases, including HIV/AIDS, malaria and other diseases. Undoubtedly, the promotion of this technology will make important contribution to the world health cause.

The rapid detection technology that the company developed can quickly get the result, and it only need one drop of blood from the subjects. The AtomoRapid product that Atomo developed to detect HIV, fuses blood sampling, blood collection and component analysis into one device. When the equipment pierced the skin surface, its built-in blood collection needle will extract 10 microlitre blood from the patients and automaticlly transport it to HIV test paper to analyze. The entire process will take no more than 15 minutes.

Researchers said that, currently, HIV detection kit need a variety of equipment used cooperatively. At the same time, this detection process is separated from each other, and some still need manual operation. These independent links may result in many problems that can affect the test results. AtomoRapid product units those various steps as one, to make sure the  rapidity and accuracy of the detection process.

The company hopes this product can be widely promoted in the future, and replace some traditional detection methods. Furthermore, the company also introduces AtomoRapid Malaria for malaria test. This product can not only rapidly detect whether the patients are infected with malaria, but also can identify the types of malaria. And at present, the company still use this technology platform to develop new products to detect Hepatitis C.